Preliminary results revealed that in patients with large B-cell lymphoma, high-dose CTX110 monotherapy resulted in an objective response rate (ORR) of 58% and a complete response (CR) rate of 38%, with good safety.443 B-cell maturation antigen (BCMA) is considered a potential target in multiple myeloma. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.